Results 91 to 100 of about 718,683 (284)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

, 2019
Xuan Jiang, Weihua Li, Xiaoying Li, Huimin Bai, Zhenyu ZhangDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaAbstract: Poly (ADP-ribose) polymerase (PARP) inhibitors
Li W, Li X, Zhang Z, Jiang X, Bai H
core  

EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple‐Negative Breast Cancer Progression

Advanced Science, EarlyView.
Endothelin receptor type A (EDNRA) and the Hippo/YAP pathway form a self‐reinforcing loop that sustains triple‐negative breast cancer. EDNRA activates YAP through Gαq/11–Rho/ROCK–LATS signaling, while YAP/TEAD4 reciprocally drives EDNRA transcription.
Zehao Hong, Boyang Li, Jiahui Xu, Ruonan Lin, Jinghao Pan, Chenlu Fang, Boxiang Zhang, Lucy Yue Lau, Richard J. Aldridge, Elizabeth A. Whitmore, Yi Chen   +10 more
wiley   +1 more source

Fibrillarin Resists Cellular Senescence Via SIRT1‐Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
FBL directly binds to and stabilizes SIRT1 by blocking its ubiquitin‐proteasome degradation, thereby sustaining nicotinamide metabolism and redox homeostasis to counteract cellular senescence in ESCC. Genetic and pharmacological suppression of FBL sensitizes tumor cells to senolytic therapy.
Xing Jin, Hong Liu, Ling Gao, Lei Liu, Ji‐Bin Liu, Xiaoxia Jin, Ming‐Song Wang, Dan Liu, Li Feng, Wen‐Lian Chen   +9 more
wiley   +1 more source

Role of akt activation in PARP inhibitor resistance in cancer

, 2020
Poly(ADP-ribose) polymerase (PARP) inhibitors have recently been introduced in the therapy of several types of cancers not responding to conventional treatments.
Szabo, Csaba, Gallyas, Ferenc, Sumegi, Balazs   +2 more
core   +2 more sources

Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1-5

, 2011
Copyright information:Taken from "Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1"http://www.biomedcentral.com/1471-2199/8/96BMC Molecular Biology
Sylvain L Guérin (83633), Serge Desnoyers (83632), Steeve Leclerc (22751), Karine Zaniolo (83631)   +3 more
core   +1 more source

TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers

Advanced Science, EarlyView.
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei, Changning Xue, Mengna Li, Jianxia Wei, Lemei Zheng, Shipeng Chen, Yijie Wang, Yumei Duan, Yanwei Luo, Wei Xiong, Ming Zhou   +10 more
wiley   +1 more source

Nanoparticle‐Mediated TIPE1 mRNA Delivery Enhances Paclitaxel Sensitivity in Triple‐Negative Breast Cancer by Modulating RAB7A Ubiquitination‐Associated Stability and Autophagy

Advanced Science, EarlyView.
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu, Qishuai Chen, Yan Ma, Yang Liu, Xianing Dong, Wenjuan Wei, Jianxin Du, Shusheng Qiu, Maojin Tian, Peiqing Zhao   +9 more
wiley   +1 more source

PARP inhibitors for prostate cancer

Seminars in Oncology
Poly(ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in DNA damage response genes. This has also led to widespread use of genomic testing in all patients with mCRPC.
Ossian Longoria, Nick Beije, Johann S. de Bono   +2 more
openaire   +2 more sources

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer

, 2018
Ilaria Colombo, Stephanie Lheureux, Amit Manulal Oza Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada Abstract: Rucaparib is a potent small-molecule inhibitor of poly (ADP ...
Colombo I, Oza AM, Lheureux S
core  

Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1-7

, 2011
Copyright information:Taken from "Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1"http://www.biomedcentral.com/1471-2199/8/96BMC Molecular Biology
Sylvain L Guérin (83633), Serge Desnoyers (83632), Steeve Leclerc (22751), Karine Zaniolo (83631)   +3 more
core   +1 more source